VEGFR-2 inhibitors (Santen Pharmaceutical)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameVEGFR-2 inhibitors (Santen Pharmaceutical)
Drug Alias Namevatalanib analogs (Santen Pharmaceutical)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsAngiogenesis disorder
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSanten Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanten Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsAngiogenesis disorder

Other Information

ATC CodeN/A
Related LinksN/A